Rare condition

Female infertility due to zona pellucida defect

0

studies recruiting now

as of 7 Sept 2026

0

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No registered studies found for Female infertility due to zona pellucida defect.

ClinicalTrials.gov has no study listed under this name as of 7 Sept 2026. That can change, and there are other routes worth knowing about.

Keep watching

Get an email when a new Female infertility due to zona pellucida defect study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Female infertility due to zona pellucida defect

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (ZP2, ZP3, ZP1).

Treatments being studied

9 approved treatments and 9 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Menotropins (Gynogen hp)Approved: Urofollitropin (Bravelle)Approved: ClomipheneApproved: Choriogonadotropin Alfa (Ovidrel)Approved: Follitropin Beta (Fertavid)Approved: Follitropin Alfa (Bemfola)Approved: Lutropin Alfa (Lutropin alfa component of pergoveris)Approved: Ganirelix (Orgalutran)Approved: Clomiphene Citrate (Clomid)
Phase 3Acetylcysteine (A-cys)
Phase 3Progesterone (Crinone)
Phase 3Dydrogesterone (Duphaston)
Phase 3Gonadorelin Acetate (Gnrh)
Phase 1/2Gestodene
Phase 1/2Ethinyl Estradiol (Estinyl)
Phase 1/2Somatropin (Genotropin)
Phase 1Follitropin

+ 1 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).